N/A
N=86
Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)
Type 2 Diabetes Mellitus
Bottom Line
View on ClinicalTrials.gov: NCT01033773 ↗Enrolled (actual)
86
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcome: Primary: Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit — 0 events
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin (Drug); Diabetes survival skills self-management education (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medstar Health Research Institute
- Primary completion
- Nov 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit |
— | — |
| SECONDARY Change in Mean Blood Glucose From Time of Presentation to Emergency Room to End of Intervention 30 Days From Baseline |
356; 183 | — |
| SECONDARY Change in Hemoglobin A1C From Baseline to End of Intervention at 30 Days |
12.0; 11.6 | — |
Summary
To demonstrate that a focused Emergency Department (ED) intervention for uncontrolled hyperglycemia enables safe and effective glycemic management and reduces emergency room re-visits. We assessed hypoglycemia BG < 60mg/dL; change in mean blood glucose and A1C, and ED revisits for hyperglycemia.
Eligibility Criteria
Inclusion Criteria
- Age > 18 years
- Type 2 Diabetes Mellitus,
- random BG > 200 mg/dL,
- willing and able to provide informed consent and to participate in diabetes self-management education (DSME)
- stable for discharge from the ED once hyperglycemia treatment initiated.
Exclusion Criteria
- type 1 Diabetes Mellitus,
- diabetic ketoacidosis or hyperosmolar non-ketotic state,
- concomitant treatment with glucocorticoids (other than stable maintenance dose therapy),
- cognitive or physical impairment preventing participation in DSME
- unwillingness or inability to provide consent and/or attend follow-up visits.
Data sourced from ClinicalTrials.gov (NCT01033773). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.